Clark, J I <br/><br/>
A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2002 
 - 606-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdf105  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Recombinant Proteins<br/>Survival Analysis<br/>Treatment Outcome